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The haemolytic uremic syndrome is characterized by microangiopathic haemolytic anaemia, 
thrombocytopenia and acute renal failure and is the most common in children under the age of 4. The 
etiology can be associated with some infectious agents like Streptococcus pneumoniae. We review the case 
of a 2-year-old girl presenting with invasive pneumococcal disease followed by the haemolytic uremic 
syndrome. The onset of the haemolytic uremic syndrome clinical manifestation was preceded by un upper 
respiratory tract infection. The physical finding was in extremely bad condition with pallor. She was 
adinamic, confused, dispnoic, dehydrated with peripheral circulatory failure. Tubular breath sounds with moist 
rales on both sides of the lung were registered as well as liver and spleen enlargement. Presenting clinical and 
laboratory data we confirmed that, in our case, following the invasive pneumococcal disease 
(pleuropneumonia, sepsis and septic shock), Streptococcus pneumoniae was the trigger of HUS. High doses of 
corticosteroids, fresh frozen plasma, antibiotics, and intravenous immunoglobulins were a successful treatment.  




Hemolitičko-uremički sindrom karakterizira mikroangiopatska hemolitička anemija, trombocitopenija i 
akutno zatajenje bubrega. Najčešće se javlja u djece u dobi mlađoj od 4 godine. Etiologija je povezana s 
nekim infektološkim agensima kao što je Streptococcus pneumoniae. Prikazali smo slučaj dvogodišnje 
djevojčice s invazivnom pneumokoknom bolesti s hemolitičko-uremičkim sindromom. Bolest je počela 
infekcijom gornjeg respiratornog trakta. Djevojčica je primljena u vrlo teškom stanju, ekstremno blijeda, 
adinamična, konfuzna, dispnoična, dehidrirana u kolapsu periferne cirkulacije. Obostrano nad plućima čuli 
su se brojni bronhitički hropci, a jetra i slezena su bile uvećane. Klinički i laboratorijski potvrdili smo da je u  
djevojčice pneumokokna invazivna bolest (pleuropneumonija, sepsa i septički šok) uzrokovana 
Streptokokom pneumonije potaknula nastanak hemolitičko-uremičkog sindroma. Uspješno izlječenje 
postignuto je primjenom visokih doza kortikosteroida, svježe smrznute plazme, antibiotika i intravenoznih 
imunoglobulina. 





The haemolytic uremic syndrome (HUS) is an 
acquired hematological disorder largely affecting 
infants and young children. Microangiopathic 
hemolytic anemia, acute renal failure, and 
thrombocytopenia are the symptoms of this 
syndrome. HUS with unknown etiology is most 
common in children under the age of 4. It has most 
often been associated with enterohaemorrhagic 
Escherichia coli  O157:H7 and some infectious agents 
like Streptococcus pneumoniae.1,2,3,4,5,6,7,8 Renal 
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biopsy samples show vasculopathy as a consequence 
of the thrombosis of the arteriolar and glomerular 
microcirculation. Trombocytopenia is the result of  
platelet consumption. Some authors published HUS 
events in children who underwent hematopoietic stem 
cell transplantation for various malignances and 
others cyclosporine or chemotherapy related.9,10,11  
HUS is the most common cause of acute renal 
failure in childhood resulting from mechanical 
damage to the red blood cells as they pass through the 
altered vasculature. Some divide the HUS Clinical 
syndrome into two groups: diarrhoea-associated HUS 
(D+HUS) mainly affecting children under the age of 
5 years, while non-diarrhoea-associated HUS (D-
HUS) are rare in children.  D-HUS characterised triad 
of HUS without diarrhoeral prodrome, and some 
authors define it as atypical HUS (aHUS).12  
Streptococcus pneumoniae associated HUS (SP-
HUS) may occur in all seasons.2 Pneumococci 
produced neuraminidase and remove the N-acetyl-
neuraminic acid from cell membrane surfaces 
exposing the Tomsen-Friedenreich antigen present on 
erythrocytes, platelets, and glomerular capillary walls 
to circulating blood elements.2,13 Antigen-antibody 
interaction results in hemolysis, thrombocytopenia 
and renal microangiopathy. Immune complexes may 
have contributed to the endothelial injury and the 
pathogenesis of HUS.14 HUS diagnosis can be 
established by clinical and laboratory findings such as 
normocytic and normochromic anemia with high 
reticulocite count, the evidence of burr cells or 
schistocytosis on the periferal blood smear, platelet 
count  bellow 100 x 109/L, marked elevation of blood 
urea nitrogen and serum creatinine. Depending on   
the degree of haemolysis, there is an increase in 
reticulocytes, plasma lactate dehydrogenase, 
unconjugated bilirubin, ferritin, with a decrease in 
serum haptoglobin levels. Those parameters are very 
sensitive and it is a way to control the intensity of 
haemolysis. 
HUS usually is not associated with plasma 
coagulation abnormalities or diffuse intravascular 
coagulopathy (DIC). DIC is rare in HUS, and plasma 
coagulation abnormalities are highly suggestive of 
septicaemia as the cause of HUS.8 The mortality rate 
during the acute phase is high (3-5%), but early 
recognition and proper treatment may result with a 




We review the case of a previously healthy 2-year-
old girl presented in extremely bad condition at the 
time of admission. An upper respiratory tract 
infection and bilateral pneumonia eight days earlier, 
with persistent fever, pallor, and weakness preceded 
the onset of clinical manifestation. At home she was 
treated with a cephalexin and azitromycin, but 
aggravation of the symptoms proceeded.  
Physical examination on admission to hospital 
revealed lethargy, and dehydration. She was 
extremely pale with jaundice, adinamic, confused, 
dysponic, dehydrated with a pallor and peripheral 
circulatory failure. On both sides of the lung tubular 
breath sounds with moist rales were confirmed. The 
liver was enlarged by 5 cm, and the spleen by 3 cm. 
Initial laboratory findings were ESR 160 mm./hr.: 
WBC 98,6 x 109/L; RBC 1, 8 x 1012/L; haemoglobin 
5,1 g/dl; haematocrit 15,0%; platelet count 106 x 
109/L; reticulocytes 115‰. There was no evidence of 
burr cells or schistocytosis on the peripheral blood 
smear.  
Direct, indirect and monospecific Coombs test was 
negative, AST 110 U/l, ALT 69 U/l, LDH 2247 U/l, 
feritin 2686 ng/ml, haptoglobin  0,113 g/l, blood urea 
44.4 ml/l, and creatinin 116 umol/l, acidum uricum 
1014 umol/l, prothrombin time (PT 3) 26,8”, APTV 
27”, fibrinogen 4,0 g/l, Factor II 25%, Factor V 30%, 
Factor VII 21%, Factor VIII 55%, fibrin degradation 
products (FDP) 256 ug/ml, potassium 2,8 mmol/l, 
sodium 131,0 mmol/l, chloride 92 mmol/l, calcium 2, 
47 mmol/l, magnesium 0,98 mmol/l.  Streptococcus 
pneumoniae grew on blood culture and on pharyngeal 
swab. Urinalysis showed mild proteinuria. 
Ultrasound showed enlargement of the kidneys 
with hyperechogenic changing in parenchyma. A 
chest radiograph showed that the child had clinical 
and radiographic evidence of both sided pleuro-
pneumonia. 
A bone marrow examination confirmed normal 
megakaryocytopoiesis with erythroid hyperplasia 
with dyserythropoietic elements.  
Three days after admission she manifested melena. 
Intravenous antibiotics (vancomycin, amycacin, 
ceftazidim, and eight days after ceftriakson) were 
started. Fluid balance management was ordered 
because of hypovolemia caused by vomiting. She was 
treated with high doses (10 mg/kg) of methyl-
prednisolone for nine days, with subsequent tapering 
till the 42nd day. She received transfusion of packed 
erythrocytes and fresh frozen plasma for the first two 
days. Supportive therapy such as alopurinol, 
furosemid, intravenous immunoglobulins (IVIG), and 
multivitamines were given. Because of iron defi-
ciency, oral administration of ferrous proteinsukci-
nilate was ordered. After 36 days, she reached 
complete stabile remission. Ten years later, our 
patient was healthy without any consequences. 





HUS occurs with some systemic conditions and 
treatment of the triggering cause is very important.8 It 
is a rare but severe complication of invasive 
pneumococcal infection in children. Patients with  
SP-HUS commonly have a pneumonia or meningitis 
and have poor clinical outcome.16  
An increased incidence of SP-HUS has been noted 
in the United Kingdom between January 1998 and 
May 2005. Its frequency has increased compared with 
historic surveys, and early mortality remains high.17  
In children with SP-HUS, pneumococcal 
pneumonia with empyema is the most common 
precipitating illness (67%), while pneumococcal 
meningitis (17%), pneumonia with bacteremia (8%), 
and pneumonia with meningitis (8%) are less 
frequent. SP-HUS patients have more severe renal 
and hematologic disease than D+ HUS patients. 
However DIC can also occur in these children.18  
Some authors revealed cytokine disturbances in 
patients with HUS. Tumor necrosis factor (TNF) may 
play the role in the pathogenesis of HUS.19 Elevated 
granulocyte-colony-stimulating-factor (G-CSF) serum 
concentrations with leucocytosis may be found.20 
Several studies of cytokine levels such as IL-6 and 
TNF-α in the serum of the HUS patients suggested 
that IL-6 plasma levels were significantly 
elevated.21,22 The exact consequences of elevated IL-6 
serum concentrations are still unknown, such as the 
cause of those elevations.  
New investigations indicate that corticosteroids 
are immunomodulators that inhibit the action of 
various cytokines.23 Steroids seem to be associated 
with a more rapid decline in serum creatinine levels.24 
Endogenous glucocorticoid secretion attenuates HUS 
severity in mice.25  
Acute mortality remains high in patients with SP-
HUS (18.9%).16 Most patients die in the early phase. 
High doses of corticosteroids (10 mg/kg) were 
beneficial in the presented HUS case, and our patient 
achieved a complete remission without any 




Our report suggests that it is extremely important 
to recognize SP-HUS very early, and start adequate 
treatment. This complication, associated with DIC, 
our patient expressed following invasive bilateral 
pneumococcal pleuropneumonia, sepsis and septic 
shock. High doses of corticosteroid, fresh frozen 
plasma, antibiotics, and IVIG were a successful 
treatment. Such therapeutic approach may increase 
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